Fulminant chemical ventriculomeningitis following intrathecal liposomal cytarabine administration. 2011

Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
University of Michigan Medical School, Ann Arbor, MI, USA.

Intrathecal liposomal cytarabine (ITLC) has shown prolonged time to neurological deterioration in some patients with leptomeningeal spread of breast cancer. We describe a patient with fulminant chemical ventriculomeningitis leading to cerebral edema and death following ITLC administration. A 56-year-old Caucasian female developed progressive headache, depressed level of consciousness and adventitious movements immediately following ITLC. Neurological examination was normal prior to injection. This progressed to loss of all brainstem function and a head CT scan demonstrated diffuse cerebral edema. Due to the absence of neurological function on examination, the family opted to withdraw care. To our knowledge we report the first patient with fulminant chemical ventriculomeningitis leading to cerebral edema and death following ITLC administration. Adjunctive glucocorticoids are recommended. Treatment options are limited and complicated by the liposomal formulation of intrathecal cytarabine.

UI MeSH Term Description Entries
D007278 Injections, Spinal Introduction of therapeutic agents into the spinal region using a needle and syringe. Injections, Intraspinal,Injections, Intrathecal,Intraspinal Injections,Intrathecal Injections,Spinal Injections,Injection, Intraspinal,Injection, Intrathecal,Injection, Spinal,Intraspinal Injection,Intrathecal Injection,Spinal Injection
D008081 Liposomes Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. Niosomes,Transferosomes,Ultradeformable Liposomes,Liposomes, Ultra-deformable,Liposome,Liposome, Ultra-deformable,Liposome, Ultradeformable,Liposomes, Ultra deformable,Liposomes, Ultradeformable,Niosome,Transferosome,Ultra-deformable Liposome,Ultra-deformable Liposomes,Ultradeformable Liposome
D008581 Meningitis Inflammation of the coverings of the brain and/or spinal cord, which consist of the PIA MATER; ARACHNOID; and DURA MATER. Infections (viral, bacterial, and fungal) are the most common causes of this condition, but subarachnoid hemorrhage (HEMORRHAGES, SUBARACHNOID), chemical irritation (chemical MENINGITIS), granulomatous conditions, neoplastic conditions (CARCINOMATOUS MENINGITIS), and other inflammatory conditions may produce this syndrome. (From Joynt, Clinical Neurology, 1994, Ch24, p6) Pachymeningitis,Meningitides,Pachymeningitides
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000964 Antimetabolites, Antineoplastic Antimetabolites that are useful in cancer chemotherapy. Antineoplastic Antimetabolites
D017809 Fatal Outcome Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept. Fatal Outcomes,Outcome, Fatal,Outcomes, Fatal

Related Publications

Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
January 2011, Journal of neurology,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
August 2008, Leukemia & lymphoma,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
September 2007, Leukemia & lymphoma,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
October 2018, Annales de biologie clinique,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
November 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
February 2014, Clinical pharmacokinetics,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
November 2008, Annals of hematology,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
August 2013, Anticancer research,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
October 2017, CNS oncology,
Arene Butto, and Wajd N Al-Holou, and Larry Junck, and Oren Sagher, and Jeffrey J Fletcher
October 2009, Journal of neuro-oncology,
Copied contents to your clipboard!